Why is Marksans Pharma falling/rising?

As of 23-Jul, Marksans Pharma Ltd is experiencing a decline in its stock price, currently at 238.15, which reflects a decrease of 3.9 or 1.61%. The stock has been underperforming, having fallen consecutively for the last six days, resulting in a total decline of 9.1% during this period. Today's performance shows that it underperformed its sector by 2.12%, and it touched an intraday low of Rs 236.4. Despite a high management efficiency indicated by a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, the stock's long-term growth prospects appear poor, with operating profit growth at only 2.87% annually over the last five years. Additionally, the stock is trading at a premium valuation compared to its peers, which may deter potential investors.
In the broader market context, the Sensex has shown a slight increase of 0.11% over the past week, contrasting with Marksans Pharma's significant decline of 8.40% during the same period. While the stock has generated a positive return of 27.80% over the past year, its recent performance indicates a disconnect with the overall market trend. The rising investor participation, with a notable increase in delivery volume, suggests some interest despite the recent downturn. However, the flat results reported in March and the low inventory turnover ratio may contribute to investor caution, leading to the stock's current downward trajectory.